All In Biotech

Drug Trial Radar · NCT04567550

RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME)

A Phase 2, Randomized, Controlled, Dose-escalation Study to Evaluate the Efficacy, Safety, and Tolerability of RGX-314 Gene Therapy Delivered Via a Single Suprachoroidal Space (SCS) Injections in Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME)(ALTITUDE)

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 139 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

139

Actual

Start

Nov 20, 2020

Primary completion

Jun 18, 2026

Study completion Jun 18, 2026

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
Collaborators
REGENXBIO Inc.
First posted
Sep 28, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 25 years, up to 89 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

ABBV-RGX-314 is being developed as a novel, potential one-time gene therapy treatment for the treatment of Diabetic Retinopathy (DR) with and without Center-Involved Diabetic Macular Edema (CI-DME). DR is a chronic and progressive complication of diabetes mellitus. It is a sight-threatening disease characterized in the early stages by neuronal and vascular dysfunction in the retina, and later by neovascularization that leads to further deterioration of functional vision. Despite the availability of current treatments, diabetic retinopathy remains the leading cause of vision loss in working-age adults, those between the ages of 20 and 74. Existing treatment with anti-VEGF agents, although shown to be effective, are limited by short therapeutic half-lives, which then require frequent intravitreal injections over the patient's lifetime, resulting in increased risk of associated adverse events and significant treatment burden. Due to the burden of treatment, patients often do not closely adhere to treatment regimens and experience sub-optimal outcomes and a decline in vision.

Conditions

  • Diabetic Retinopathy (DR)
  • Center-Involved Diabetic Macular Edema (CI-DME)

Interventions

  • ABBV-RGX-314 Dose 1Genetic

    AAV8 vector containing a transgene for anti-VEGF fab (Dose 1)

  • ABBV-RGX-314 Dose 2Genetic

    AAV8 vector containing a transgene for anti-VEGF fab (Dose 2)

  • ABBV-RGX-314 Dose 3Genetic

    AAV8 vector containing a transgene for anti-VEGF fab (Dose 3)

  • Topical SteroidDrug

    Topical Steroid

  • ABBV-RGX-314 Dose 4Genetic

    AAV8 vector containing a transgene for anti-VEGF fab (Dose 4)

  • AfliberceptBiological

    Aflibercept

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Proportion of participants achieving a 2-step or greater improvement in DR in the study eye per the ETDRS-DRSS on 4 widefield digital stereoscopic fundus photography at Week 48Time frame: At Week 48
  2. Part 2: Mean change from baseline in Best Corrected Visual Acuity (BCVA) in the study eye at Week 54.Time frame: At Week 54

Locations

25 sites in 1 country. Site status is shown where the registry gives one.

  • Retinal Research Institute, LLC

    Phoenix, Arizona

  • Barnet Dulaney Perkins Eye Center

    Phoenix, Arizona

  • California Retina Consultants

    Bakersfield, California

  • Retina-Vitreous Associates Medical Group

    Beverly Hills, California

  • Retinal Diagnostic Center

    Campbell, California

  • Northern California Retina Vitreous Associates Medical Group, Inc.

    Mountain View, California

  • California Eye Specialists Medical Group, Inc

    Pasadena, California

  • Retinal Consultants San Diego

    Poway, California

  • California Retina Consultants

    Santa Barbara, California

  • Southeast Retina Center, PC

    Augusta, Georgia

  • University Retina and Macula Associates, PC

    Oak Forest, Illinois

  • Springfield Clinic

    Springfield, Illinois

  • Wilmer Eye Institute/Johns Hopkins University School of Medicine

    Baltimore, Maryland

  • Cumberland Valley Retina Consultants

    Hagerstown, Maryland

  • Ophthalmic Consultants of Boston

    Boston, Massachusetts

  • Sierra Eye Associates

    Reno, Nevada

  • NJ Retina

    Teaneck, New Jersey

  • Vision Research Center Eye Associates of New Mexico

    Albuquerque, New Mexico

  • Duke University Eye Center

    Durham, North Carolina

  • Mid Atlantic Retina

    Philadelphia, Pennsylvania

  • Charles Retina Institute, P.C.

    Germantown, Tennessee

  • Retina Research Institute of Texas, LLC

    Abilene, Texas

  • Austin Clinical Research, LLC

    Austin, Texas

  • Star Retina

    Burleson, Texas

  • Retinal Consultants of Texas

    The Woodlands, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.